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Available online 10 November 2016DNAﬂap endonuclease 1 (FEN1) plays critical roles inmaintaining genome stability and integrity byparticipating
in both DNA replication and repair. Suppression of FEN1 in cells leads to the retardation of DNA replication and
accumulation of unrepaired DNA intermediates, resulting in DNA double strand breaks (DSBs) and apoptosis.
Therefore, targeting FEN1 could serve as a potent strategy for cancer therapy. In this study, we demonstrated
that FEN1 is overexpressed in breast cancers and is essential for rapid proliferation of cancer cells. We showed
thatmanipulating FEN1 levels in cells alters the response of cancer cells to chemotherapeutic drugs. Furthermore,
we identiﬁed a small molecular compound, SC13 that speciﬁcally inhibits FEN1 activity, thereby interfering with
DNA replication and repair in vitro and in cells. SC13 suppresses cancer cell proliferation and induces chromo-
some instability and cytotoxicity in cells. Importantly, SC13 sensitizes cancer cells to DNA damage-inducing ther-
apeutic modalities and impedes cancer progression in amousemodel. These ﬁndings could establish a paradigm
for the treatment of breast cancer and other cancers as well.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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DNA ﬂap endonuclease 1 (FEN1) represents a unique class of struc-
ture-speciﬁc 5′ endonucleases (Shen et al., 2005). Unlike many other
endonucleases that recognize a speciﬁc DNA sequence, FEN1 recognizes
a speciﬁc DNA structure, independent of the DNA sequence (Shen et al.,
2005). FEN1 has three distinct activities: 5′ ﬂap endonuclease (FEN),
exonuclease (EXO), and gap-dependent endonuclease (GEN) activities.
FEN activity, the most dominant activity of FEN1, plays a major role in
RNAprimer removal duringOkazaki fragmentmaturation of the lagging
strand during DNA replication and in the removal of ﬂap structures
formed during long-patch (LP) base excision repair (BER)
(Balakrishnan and Bambara, 2013). Thus, FEN1 has dual functions in
DNA replication and repair and is essential for genome stability and in-
tegrity. Deﬁciencies in FEN1 function or deletion of the FEN1 gene have
profound biological effects. Mouse model studies showed that FEN1.
. This is an open access article underdeﬁciency causes defects in DNA replication, failure of cell proliferation,
and embryonic lethality (Kucherlapati et al., 2002; Zheng et al., 2007a).
Moreover, mouse embryonic ﬁbroblasts (MEFs) having defective FEN1
are sensitive to DNA damaging agents such as methyl methane sulfo-
nate (MMS) and γ-radiation (Larsen et al., 2003; Zheng et al., 2007b).
Due to its fundamental role in DNA replication, FEN1 is required to
support hyper-proliferation of cancer cells. Indeed, there is growing ev-
idence that FEN1 expression is associated with the onset and progres-
sion of cancer. FEN1 is expressed at low levels in quiescent cells (Kim
et al., 2000), but is highly expressed in proliferative tissues and cancers
including lung (Nikolova et al., 2009), breast (Singh et al., 2008), gastric
(Wang et al., 2014), prostate (Lam et al., 2006), pancreatic (Iacobuzio-
Donahue et al., 2003) and brain cancers (Krause et al., 2005). Moreover,
the level of FEN1 expression in cancer tissues has been correlated with
increased cancer grade and aggressiveness (Abdel-Fatah et al., 2014).
Thus, we propose that inhibiting FEN1 activity could suppress cancer
cell growth.
Most chemotherapeutic drugs used clinically evoke cell apoptosis by
inducing DNA damage. However, the high efﬁciency of DNA repair due
to the overexpression of DNA repair proteins in cancer cells reduces thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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pression level of DNA polymerase beta (Pol β) has been correlated with
resistance of cancer cells to chemotherapeutic drugs (Lawson et al.,
2011). Cells with higher levels of DNA ligase IV exhibit reduced levels
of γ-H2AX foci (an early marker of DNA damage in cells) upon treat-
ment with DNA damage agents (Srivastava et al., 2012). Moreover, pa-
tients with DNA repair efﬁciency defects are more sensitive to
chemotherapy (Riballo et al., 1999). Based on the roles of FEN1 in
DNA repair, we speculate that inhibition of FEN1 could lead to the gen-
eration of DNA lesions, thus sensitize cancer cells to chemotherapy.
Breast cancer remains the most common cancer in females, and its
incidence continues to rise (Hutchinson, 2010). There is an urgent de-
mand for novel drugs effective in treating breast cancer. In this study,
we showed that FEN1 is overexpressed in breast cancer. Using the
MCF7 breast cancer cell line as a research model, we demonstrated
that FEN1 is essential for proliferation and drug resistance in breast can-
cer cells. Furthermore, we identiﬁed a FEN1 inhibitor, SC13. SC13 blocks
FEN1 activity speciﬁcally and impairs DNA replication and repair in vitro
and in cells. SC13 suppresses cell growth, resulting in the accumulation
of DNA double strand breaks (DSBs) in cells, thereby culminating into
cytotoxicity. Finally, using mouse cancer models, we showed that
SC13 impedes progression of cancer growth, causing a signiﬁcant in-
crease in the sensitivity of cancers toward chemotherapy.
2. Materials and Methods
2.1. Cell Lines and Cell Culture
All cell lines used in this study were from the American Type Tissue
Collection and were cultured under conditions as directed by the prod-
uct instructions.
2.2. Immunochemistry Analysis
Tissues were ﬁxed in 10% formalin. Parafﬁn-embedded sections
from tissue specimens were de-parafﬁnized and heated at 97 °C in
10 mM citrate buffer (pH 6.0) for 20 min for antigen retrieval. Primary
antibodies used in immunocytochemistrywere raised against FEN1. Im-
munoreactivities were analyzed by estimating the percentage of cells
showing characteristic staining and the intensity of staining (Elakoum
et al., 2014). The intensity of staining was graded as 1 (weak), 2 (medi-
um), or 3 (strong). Resultswere scored bymultiplying the percentage of
positive cells (P) by the intensity (I) to obtain the Q-score (Q), which
ranged between 0 and 300. A Q-score of 300 represented 100% of cells
strongly stained (Q = P × I; maximum = 300) (Elakoum et al., 2014;
Wu et al., 2011).
2.3. FEN1 Nuclease Activity Assay
The cleavage of DNA substrates by FEN1 was determined under the
same conditions as those previously published (Guo et al., 2008; Sun et
al., 2016). Double ﬂap DNA substrate (a long 5′ ﬂap and a short 3′ falp)
has been reported as the best substrate for Flap activity (Finger et al.,
2009; Tsutakawa et al., 2011; Kao et al., 2002; Friedrich-Heineken and
Hubscher, 2004). Brieﬂy, 32P-labeled DNA substrates were incubated
with puriﬁed FEN1 in a buffer solution containing 50 mM Tris-HCl
(pH 8.0), 50 mM NaCl, and 5 mM MgCl2. The reactions were carried
out at 37 °C for 30 min and were terminated with stop solution (95%
formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05% xylene
cyanol). The product and substrate were then separated by 15% PAGE
and visualized by autoradiography.
2.4. DNA Replication Efﬁciency Assay
DNA replication efﬁciency of cellswasmeasured by 3H incorporation
assay (Sun et al., 2016). Brieﬂy, 5 × 104 cells were seeded onto a 6-cmdish in Dulbecco's Modiﬁed Eagle Medium (DMEM) for 12 h. 3H-thymi-
dine was added to a ﬁnal concentration of 1 μCi/mL. Cells were incubat-
ed in 3H-thymidine-containing DMEM for a speciﬁc time period and
washed with ice-cold PBS buffer. DNA was precipitated by treating
cells with 10% ice-cold trichloroacetic acid and 10 mM thymidine
(15 min, 4 °C). After washing extensively with PBS buffer, DNAwas sol-
ubilized in 0.5 M NaOH. Radioactivity levels in the sample were mea-
sured using a liquid scintillation counter.
2.5. Okazaki Fragment Maturation Assay
Okazaki fragment maturation was assayed according to published
protocols (Zheng et al., 2007a, 2007b; Jaiswal et al., 2011). Brieﬂy, cell
extracts were incubated with speciﬁc gapped substrates in a reaction
buffer containing 5 μCi [α-32P]dCTP and 50 μM each of dATP, dGTP,
dTTP, and 2 mM ATP. Reactions were carried out (60 min, 37 °C) and
products were separated by 15% denaturing PAGE, followed by
autoradiography.
2.6. Base Excision Repair Assay
The BER assay was performed as described previously (Guo et al.,
2009; Zhou et al., 2016). Reactions were carried out in 20 μl of reaction
buffer B (40 mM HEPES-KOH [pH 7.8], 70 mM KCI, 7 mMMgCl2, 1 mM
dithiothreitol, 0.5 mM EDTA, 2 mMATP, 50 μM each of dATP, dTTP, and
dGTP, and 2 μCi [α-32P]-dCTP). For SP reconstitution with puriﬁed pro-
teins, Uracil-DNA Glycosylase (UDG, 8 ng), APE1 (2 ng), Ligase IIIα
(20 ng) and various amounts of Pol β (0–5 ng), were mixed and incu-
bated with the SP-BER substrate Pol β-U (Fig. 4e). For LP-BER, the Pol
β-F substrate (Fig. 4f) was incubated with a mixture of APE1 (2 ng),
Pol β (0–5 ng), FEN1 (2 ng), and Ligase I (20 ng). For cell extract recon-
stitution (Fig. 4c), the LP-BER DNA substrate was incubated with the
whole cell extract (WCE) (5 μg). Reactions (30 min, 37 °C) were then
stopped by adding an equal volume of the gel loading buffer and visual-
ized by autoradiography.
2.7. In vivo 8-Oxo-dG BER Assay
An extrachromosomal assay system (Sundaresakumar, 2009) using
a biotin-tagged oligonucleotide DNA substrate containing an 8-oxo-dG
lesion that can be repaired by LP-BER (Sattler et al., 2003). The 8-oxo-
dG BER assay uses a double-stranded oligonucleotide DNA substrate
that consists of a biotinylated DNA strand that is base paired to an un-
tagged DNA strand containing a single 8-oxo-dG lesion. The substrate
DNA is transfected into MCF7 cells and incubated for 4 h to allow repair
of the 8-oxo-dG lesion. SC13was added to the culturemedium to test its
effects on 8-oxo-dG repair. The cells are then lysed and the biotinylated
substrate DNA is captured using streptavidin-coated magnetic beads. In
the presence of a magnet, the strand containing the 8-oxo-dG lesion is
denatured and isolated from the streptavidin-bound biotinylated
strand. The isolated DNA is then quantiﬁed and subjected to an 8-oxo-
dG competitive ELISA using a competitive 8-oxo-dG ELISA kit (Trevigen,
Cat. No.4380-192-K).
2.8. HR Reporter Assays
U2OS cells with DR-GFP integration was used to measure homolo-
gous recombination efﬁciency as described. Speciﬁcally, 3.5 × 105
U2OS-DR-GFP cells were seeded in six-well plates per well and 24 h
later transfect plasmid pCBASce (an I-SceI expression vector) with Lipo-
fectamine 3000 under manufacture's protocol. Culture medium
contained 2 μM SC13, which will not cause signiﬁcant cell toxicity.
48 h after transfection, cells were harvested and subjected to ﬂow cy-
tometry analysis to assess the GFP positivity. Relative HR efﬁciency
was calculated and compared using CFCS and GraphPad PRISM
software.
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The sensitivity to DNA damage-inducing reagents was determined
by cell growth inhibition assays (Guo et al., 2009). MCF7 cells were
seeded (1500/well), incubated (overnight, 37 °C), treated (1 h, 37 °C)
with multiple dilutions of H2O2, washed in fresh medium (DMEM con-
taining 10% fetal bovine serum) and incubated (72 h) under normal
growth conditions (37 °C, 5% CO2). Thenumber of viable cellswasdeter-
mined by the CellTiter 96 AQueous one-solution cell proliferation assay
(Promega). At least four replicationswere performed for each clone, and
the means were calculated. Data were expressed as the percentage of
growth relative to untreated controls.
2.10. Cellular Transformation Assay
The focus formation assaywas conducted according to a previous re-
port (Chung et al., 2015). The presence of foci was visually evaluated
after staining the cells with 0.05% crystal violet. The anchorage-inde-
pendent growth assay in soft-agar was described previously (Bose et
al., 2013). Brieﬂy, the cells (3000 cells per 35mmwell) were suspended
in completemedium containing 0.35% agarose. The cells were grown on
tissue culture dishes containing a 2 mL layer of solidiﬁed 0.7% agar in a
completemedium. After 10 days, the number of colonieswas quantiﬁed
frommicrographs taken at random locations on the plate (originalmag-
niﬁcation, ×20).
2.11. Xenograft Studies
Female homozygous, 6-week-old, nude mice were used in this
study. MCF7 cells were harvested, and single-cell suspensions with
N95% viability (5 × 106 cells) diluted with equal volumes of Matrigel
(BD Biosciences) were injected subcutaneously into the right ﬂank of
each mouse. After the cancers were established, drugs were adminis-
tered intraperitoneally daily for ﬁve consecutive days. Cancer volume
was measured weekly in each group. Mice were euthanized when the
cancer volume reached ~1000 mm3. The mice were housed and main-
tained under standard NIH protocol.
3. Results
3.1. FEN1 Is Overexpressed in Breast Cancer and Co-Related to Malignancy
According to the Cancer Genome Atlas (TCGA) database, FEN1 is
overexpressed in various types of cancers, including breast, prostate,
gastric, lung, and colorectal cancers (Figs. 1a and S1a), which is consis-
tent with our previous report (Singh et al., 2008). We chose breast can-
cer for further study, as it is the most common cause of death from
cancer in females (Matsen and Neumayer, 2013). To verify the data
from the TCGA database, we collected breast cancer samples from surgi-
cal excisions and compared the levels of FEN1protein in cancer and nor-
mal tissues from the same patient using western blotting (Fig. 1b). We
found FEN1 was highly expressed in breast cancer tissue compared to
the corresponding normal tissue (Fig. 1b). In addition, FEN1 displayed
signiﬁcantly stronger staining in cancer specimens than in their healthy
counterparts in immunohistochemistry assays (Fig. 1c). The intensity of
staining was graded 1 for weak, 2 for medium and 3 for strong. Results
were scored by multiplying the percentage of positive cells (P) by the
intensity (I) that is by using the quick score (Q). A Q-score between 0
and 300 is obtained where 300 is equal to 100% of cells strongly stained
(Q = P × I, maximum= 300). Score of b100 is considered weak, and
N200 is considered strong. While82% of patients had a FEN1
score b 100 (95% CI, 78–86%) in normal tissue, a signiﬁcantly lower pro-
portion of patients (8%) displayed a FEN1 score b 100 in tumor tissues
(95% CI, 3–13%; p b 0.001). Conversely, the proportion of patients with
FEN1 scores N200 was signiﬁcantly higher in tumor than normal tissue
(78% vs. 0%; p b 0.001; Fig. 1d). Moreover, the median FEN1 expressionwas elevated signiﬁcantly in cancer tissues compared to that in the cor-
responding normal tissues (p b 0.001; Fig. 1e). Furthermore, the FEN1
protein level was overexpressed in various breast cancer cell lines
such as MCF7, MDA-MB-231 and MDA-MB-435, when compared to
the normal breast epithelial cell line, MCF10A (Fig. S1b).
Next, we investigated whether the FEN1 expression level is correlat-
ed to themalignancy of breast cancers. Data from the ATCG database in-
dicated that themalignancy grade rosewith increasing FEN1 expression
levels in breast cancers (Fig. 1f), suggesting that FEN1 overexpression is
associated with high levels of malignancy.
To validate this conclusion, we employed a tissue array of 48 breast
cancer tissues with various malignancy grades (Table S1). Table S1pre-
sents the expression pattern of FEN1 in various breast cancer tissues.
The results showed that high expression of FEN1 is associated with a
statistically signiﬁcant probability of increased malignancy (p b 0.01).
The statistical analysis of the FEN1 status in relation to TNM stage and
tumor grade was performed using the parametric Fisher's exact test
(Table S1). High expression of FEN1 appeared to associate in a statisti-
cally signiﬁcant manner with highly malignant tumors (p b 0.05) and
tumors of advanced TNM stage (p b 0.05). Moreover, consistent with
this result and our previous report (Wang et al., 2015), Kaplan-Meier
analyses revealed that breast cancer patients with high expression of
FEN1 have poor prognoses (Fig. 1g). These results suggest that FEN1 is
associated with onset and progression of breast cancer.
3.2. Overexpression of FEN1 Promotes Cell Growth and Induces Foci
Formation
To testwhether FEN1 is essential for rapid cell growth and promotes
foci formation, FEN1 is suppressed inMCF7 (high endogenous FEN1 ex-
pression, Figs. S1b, 2a) or overexpressed in MCF10A (low endogenous
FEN1 expression, Figs. S1b, 2b). Suppressing FEN1 expression in MCF7
led to retarded cell growth (Fig. 2c) and foci formation (Fig. 2e) while
overexpression of FEN1 in MCF10A promoted cell growth (Fig. 2d)
and induced foci formation (Fig. 2f). This observation was conﬁrmed
in other breast cancer cell lines (T47D, MDA-MB-231, and HCC1937)
and cell lines from various cancer types such as lung (A549) and colo-
rectal (HCT8) cancer (data not shown), indicating that this phenome-
non is not cell-line-speciﬁc. These data suggest that FEN1 is essential
for the growth of cancer cells.
3.3. FEN1 Regulates the Sensitivity of Cancer Cells to DNADamage-inducing
Agents
As FEN1 is involved in DNA repair, we speculated that manipulation
of FEN1 could alter the response of cancer cells to chemotherapeutic
drugs that induce DNA lesions. To test this, FEN1 level wasmanipulated
in cells and the survival rate of resulted cells were determined after ex-
posed to temozolomide (TMZ), a commonly used DNA damage-induc-
ing cancer drug (Chamberlain, 2010). We found that FEN1-
knockdown-treated cells show greater sensitivity to TMZ (Fig. 2g),
whereas FEN1-overexpressing cells demonstrated higher resistance to
this drug (Fig. 2h) when compared to their own control cells. To further
test whether FEN1 expression levels could impact the response of can-
cer cells to other DNA damage-inducing agents, we determined the
sub-G1 ratio (apoptotic fraction of cells) of MCF7 after treatment with
TMZ, ﬂuorouracil (5FU) and cisplatin. We found that FEN1 knockdown
augmented cell apoptosis induced by TMZ, 5FU, and cisplatin (Fig. 2i).
Overexpression of FEN1 prevented apoptosis induced by these drugs
(Fig. 2j). These data indicated that alterations in FEN1 levels might im-
pact the tumor cell response to anticancer drugs.
3.4. Screening of Small Molecular Compounds to Inhibit FEN1
Based on the observations above, FEN1 is essential for cancer cell
growth and determines the drug response of cancer cells. It is rational
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for cancer therapy. Therefore, FEN1 inhibitors could serve as potent an-
ticancer drugs, which could be used alone to suppress cancer cell
growth or combined with DNA damage-inducing agents to augment
cell apoptosis.
A previous study by Tumey et al. showed that N-hydroxyl urea de-
rivatives possess inhibitory action against FEN1 (Tumey et al., 2005).
Compound #20, with an IC50 of 3 nM to FEN activity, is themost potent
FEN1 inhibitor tested in vitro. However, its ability to suppress the
growth of cancer cells is limited when used alone (Tumey et al.,
2005). To generate a more potent anti-FEN1 compound, we designed
two series of six novel small molecules based on the N-hydroxyl urea
derivative #20 (Figs. 3a and S2a). The pharmacophores of the two series
were pyrrolo[3.2-d] pyrimidine (SC11, SC12, and SC13) and thieno[3.2-
d] pyrimidine (SC21, SC22, and SC23), respectively. To investigate the
structure-activity relationship (SAR) and to improve the cellpermeability of target compounds, the hydrophilic hydroxyl groups of
urea were substituted by hydrophobic phenyl, benzyl, and n-propyl
building blocks (Figs. 3a and S2a). Among six small molecules, SC13
(shown in Figs. 3a and 4a) displayed comparable inhibitory effects on
FEN1 activity to the N-hydroxyl urea derivative #20 (Supplementary
Fig. S3) but improved cell permeability.
To understand how SC13 interferes with FEN1, we performed
docking studies to elucidate the interacting site of SC13 to FEN1. Five
best druggable sites of the FEN1 protein were predicted using our in-
house developed Druggable Site Prediction (DSP) algorithm (Gu et al.,
2015) (Fig. 3b). Approximately 65% of the FDA-approved drugs showed
a preference for binding the best druggable site (site 1, shown in red,
Fig. 3b), while 3–7% of the drugmolecules showed a binding preference
for the other four druggable sites. SC13 binds FEN1 protein at the best
druggable site by forming four hydrogen bonds with S36, T134, N138,
and D233 (Fig. 3c). To conﬁrm the binding pocket of SC13, meta-
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3d). The 50-nsmolecular dynamics simulation shows that SC13 remains
in the pocket with a binding afﬁnity of approximately−4.2 kcal/mol.To conﬁrm the binding of SC13 to FEN1, we performed circular di-
chroism spectroscopy analysis. The results showed a clear shift in the
spectrum upon addition of SC13 to FEN1, compared to the control
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binding with FEN1 protein predicted by implementing 50 ns meta-dynamics simulation. e. Circular dichroism spectroscopy analysis of FEN1/SC13 binding. f. Inhibitory effects of SC13
on FEN1 mutations. g. Effects of SC13 on DNA substrate binding.
37L. He et al. / EBioMedicine 14 (2016) 32–43(Fig. 3e), suggesting a physical interaction of SC13 with FEN1. The data
also showed that Tumey #20 and SC13 bound to FEN1 and resulted in a
similar conformation change (Fig. 3e).
To further validate that S36, T134, N138, and D233 residues are in-
volved in the SC13/FEN1 interaction, we generated the following FEN1
mutations: S36A, T134A, N138A, and D233A. The results showed that
while the FEN activity of these mutants remained intact (with the ex-
ception of D233A, which was inactive), the inhibitory effects of SC13
were disrupted (Fig. 3f), suggesting that these residues are involved in
SC13-related FEN1 inhibition activity.
For example, as displayed in Fig. 3f, the S36Amutation itself does not
affect FEN1 activity signiﬁcantly (slightly drops to about 95%).
Meanwhile, as the binding model shown in Fig. 3c, S36 may form
hydrogen bond with SC13 molecule to enhance the inhibitor bind-
ing. Thus, S36 is a good residue for mutagenesis to validate themodel of FEN1 in complex with SC13: its mutation would not affect
FEN1 activity while the mutation might interrupt the binding of
SC13 inhibitor. Indeed, we see that the S36A mutated FEN1 activity
does not drop signiﬁcantly when SC13 is presence (slightly drops
to about 90%), while in wild-type the FEN1 activity drops dramati-
cally to about 15%. This implies that the S36A mutation effectively
blocks SC13 bound to FEN1 protein. Consequently, the S36A mutat-
ed FEN1 activity should not be affected signiﬁcantly by SC13 any-
more. Therefore, S36 should be one of the key residues to directly
contact with the FEN1 inhibitor.
To test whether SC13 binding to the active center of FEN1 impaired
DNA substrate binding, we performed a DNA-FEN1 binding assay. Sur-
prisingly, although SC13 binds to the FEN1 active center, it does not in-
terfere with FEN1-substrate binding (Fig. 3g). Moreover, we found that
SC13 did not exert any inhibitory effects on EXO activity or GEN activity
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38 L. He et al. / EBioMedicine 14 (2016) 32–43at the IC50 of FEN activity (Fig. S3c,d). Therefore, SC13 inhibit FEN activ-
ity of FEN1 speciﬁcally.
To determine whether SC13 is a speciﬁc inhibitor of FEN1 activity, we
investigatedwhether it also blocks the activity of other BER enzymes suchas apurinic/apyrimidinic endonuclease 1 (APE1), Pol β, and DNA ligase I.
We also tested the effects of SC13 on DNase I. The results showed that
SC13 did not inhibit the activities of these enzymes (Figs. S2b–d, S3d), in-
dicating that the inhibitory effect of SC13 was highly speciﬁc for FEN1.
39L. He et al. / EBioMedicine 14 (2016) 32–433.5. SC13 Interferes with Okazaki FragmentMaturation and Long Patch Ba-
se Excision Repair
As described previously, FEN1 is involved in the maturation of Oka-
zaki fragments and long patch base excision repair (LP-BER). To deter-
mine whether SC13 affects Okazaki fragment maturation, SC13 was
added to the in vitro reaction system. The results showed that SC13 de-
creased the efﬁciency of RNA primer ﬂap removal and prevented DNA
ligation (Fig. 4b), indicating the Okazaki fragmentmaturation efﬁciency
was impaired by SC13.
To test whether SC13 affected the overall LP-BER efﬁciency, we per-
formed an in vitro LP-BER reconstitution assay using cell extracts (Fig.
4c) or puriﬁed proteins (Fig. 4d). We found that while cell extracts
repaired DNA damage efﬁciently, as demonstrated by an intense 40-nt
band (Fig. 4c, lane 1), SC13 reduced the amount of repair dramatically
(Fig. 4c, lane 1 vs. 2). Interestingly, the addition of puriﬁed FEN1 re-
stored the LB-BER activity (Fig. 4c, lanes 3–5). These results indicated
that the inhibitory effect of SC13 on LP-BER is FEN1 dependent. More-
over, SC13 inhibited LP-BER (Fig. 4d), but not short patch BER (Fig. 4e)
in a reconstitution assay with puriﬁed protein, further supporting that
SC13 interferes with FEN1 activity speciﬁcally (FEN1 is not required in
the short patch BER assay).
To further evaluate the effects of SC13 on BER inside the cells, we
adopted an extrachromosomal assay system (Sundaresakumar, 2009)
using a biotin-tagged oligonucleotide DNA substrate containing an 8-
oxo-dG lesion that can be repaired by LP-BER (Sattler et al., 2003). The
substrate DNA is transfected into target cells and incubated (4 h) to
allow repair of the lesions. The DNA is then captured following cell
lysis and the disappearance of 8-oxo-dG lesions is monitored using
competitive 8-oxo-dG ELISA (Fig. 4f for assay procedure). SC13 was
added to the cell culture medium at the incubation step. To exclude
the general toxicity of SC13 on cells, we tested the effects of SC13 on
cell proliferation at the same condition. We found no cytotoxicity was
observed among the cells that were treated with SC13 for 4 h up to
250 uM (Fig. S4). In this manuscript, we chose up to 50 uM SC13 for
8-oxo-dG repair inhibition assay and all the other cell-based assays in
this study.
As shown in Fig. 4g, upon addition of SC13, a decrease in 8-oxo dG
repair was observed, suggesting that SC13 inhibited endogenous BER
at the intracellular level (Fig. 4g). As FEN1 was recently reported to be
required for homologous recombination repair (Fehrmann et al.,
2015), we speculated that SC13 might also interfere in HR repair. In-
deed, in the assay with a stably integrated GFP-based homologous re-
combination substrate (Gunn and Stark, 2012), SC13 clearly impaired
HR-mediated repair (Fig. 4h).3.6. SC13 Retards DNA Replication and Suppresses Cell Growth
The SC13-induced retarded efﬁciency of Okazaki fragment matura-
tion (Fig. 4b) might affect DNA replication in cells. Therefore, we evalu-
ated the DNA replication rate of cells with or without SC13 treatment
using a 3H-thymidine incorporation assay. The data showed that SC13
caused a signiﬁcant reduction in 3H-thymidine incorporation, indicating
DNA replication was inhibited by SC13 (Fig. 5a). As a consequence of
this reduction in DNA replication, the overall cell proliferation rate
was reduced (Fig. 5b).
A defect in the DNA replication process might arrest cells in G1
phase and decrease S and G2/M phases (Sclafani and Holzen,
2007). To test the effects of SC13 on the cell cycle proﬁle, we car-
ried out a FACS assay. As shown in Fig. 5c, SC13 treatment caused
an accumulation of cells in G1 phase but a decrease of cells in S
and G2/M phases compared to the control (Fig. 5c). These data
suggest that SC13 impeded cancer cell growth, consistent with an
impaired Okazaki fragment maturation and delayed cell cycle
progression.3.7. SC13 Leads to Generation of Unrepaired DSBs and Chromosome Breaks
in Cells
Previous reports indicated that defects in the Okazaki fragmentmat-
uration process during DNA replication or ligation during DNA repair
could lead to the accumulation of DNA DSBs (Pascucci et al., 2005).
Therefore, SC13-treated cells would be expected to display a higher
level of DNA damage.
To test this,we treated FEN1 proﬁcient cellsMCF7with SC13, follow-
ed by immunoﬂuorescence and western blotting using anti-γ-H2AX.
Results showed that in the presence of SC13, the levels of γ-H2AX in
cellswere higher than that in the control (Fig. 5d). Similarly, SC13-treat-
ment also induce the accumulation of γ-H2AX in MDA-MB-231, also
breast cancer cell line (Figs. 5e, S1). These data indicated that SC13
treatment resulted in accumulation of DNA DSBs in cells. However,
when SC13 were applied to cells with low FEN1 expression, including
Bcap37 (Fig. 5f) and MCF10A (Fig. 5g), no signiﬁcant change was ob-
served after SC13 treatment, suggesting that SC13-induced DSBs is
FEN1-dependent manner. Consistently, cells with FEN1-knockdown
do not response to SC13 treatment (Fig. S5).
HR repair is the major pathway to repair DSBs in cells (Dudas and
Chovanec, 2004). Therefore, we speculated that inhibition of HR could
augment the effects of SC13 to generate unrepaired damage in cells. In-
deed,we observed increased numbers of DNAbreakswhen the FEN1 in-
hibitor was combined with PARP1 inhibitor (Fig. 5i). Moreover, the
accumulation of DNA strand breaks in the genome may cause chromo-
some breaks (van Gent et al., 2001). Therefore, we determinedwhether
SC13 could induce such chromosomal aberrations by counting the num-
ber of chromosomes in SC13-treated MCF7 cells. We found that the
SC13-treated cells were more susceptible to the generation of chromo-
somal breaks (Fig. 5j). Thus, SC13 interferes with DNA replication and
repair in cells, leading to the accumulation of unrepaired DSBs and chro-
mosome breakage.
3.8. SC13 Induces Cytotoxicity by Targeting FEN1
The accumulation of unrepaired DSBs and chromosomal breaks in-
duce cell apoptosis (Roos and Kaina, 2013). To evaluate whether SC13
treatment leads to cell death, we treated MCF7 cells with increasing
concentrations of SC13. We showed a dose-dependent decrease in cell
proliferation of MCF7 cells, indicating the cytotoxicity of SC13 to cancer
cells (Fig. 6a). However, SC13-mediated cytotoxicitywas limited among
cells in which FEN1was knocked down (Fig. 6b) or in which FEN1 ex-
pression level is low (MCF10A cells) (Figs. 6c, S1). These data indicated
that SC13 induces cell death by targeting FEN1.
As SC13 induced more DNA breaks in cells treated with a PARP1 in-
hibitor (Fig. 5i), we speculated that SC13 ismore cytotoxic to cells when
HR is inhibited or defective. Indeed, consistentwith Fig. 5i, the combina-
tion of SC13 and PARP1 inhibitors led to more cell death than SC13 or
PARP1 inhibitor alone (Fig. 6d). HCC1937 is a breast cancer cell line har-
boring a homologous BRCA1 mutation (Tomlinson et al., 1998). It syn-
thesizes a truncated BRCA1 protein which is the product of a disease-
producing mutant allele (5382insC). The HCC1937 cell line is HR-deﬁ-
cient and we showed that this cell line is more sensitive to SC13 than
MCF7 cells (BRAC1+/+). These data indicated that in the absence of ef-
ﬁcient HR, DSBs that were accumulated due to blockage of FEN1
remained unrepaired and led to enhanced cell death (Fig. 6e). These re-
sults support previous reports, which showed a synthetic lethal interac-
tion between FEN1 and HR pathway proteins (McManus et al., 2009;
van Pel et al., 2013).
3.9. SC13 Enhances the Sensitivity of Cancer Cells to Chemotherapeutic
Agents
Based on the data above, we speculated that SC13 treatment com-
bined with chemotherapeutic drugs could enhance the frequency of
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40 L. He et al. / EBioMedicine 14 (2016) 32–43DSBs in cancer cells. The results showed that chemotherapeutic drugs
generated a higher number of γ-H2AX foci per cell upon addition of
SC13, as compared to drug alone (Fig. 7a–c). We further speculated
that combining theuse of SC13 and chemotherapeutic drugs that induce
DNA damage could enhance the sensitivity of cancer cells. To test this,
we determined the cell sensitivity to SC13 alone or in combination
with chemotherapeutic drugs. The results showed that the combina-
tions of SC13with cisplatin, TMZ, or 5FU increased the sensitivity of can-
cer cells to these drugs (Fig. 7d–f, respectively). However, the sensitivity
to the combination treatment was reduced in cells where FEN1 is low
expressed (Fig. 7g) or knockdown (Fig. 7h). These results demonstratedthat SC13 in combinationwith additional chemotherapy drugs could be
used as a more effective strategy for treating cancers.
To verify the in vitro results that showed efﬁcacy with the combined
treatment of SC13 and DNA damage reagents, we performed an in vivo
xenograft study using nude mice, as described in Fig. 7i. Ten days after
cell injection, the drugs were given intra-peritoneally daily for ﬁve con-
secutive days, and the cancer growth inhibition was monitored up to
40 days. The tumor volume increased in the control group in a time-de-
pendent manner (Fig. 7i), but decreased in mice treated with cisplatin
or SC13 alone. However, the tumor inhibitory effect was much more
pronounced when SC13 was combined with cisplatin, suggesting that
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41L. He et al. / EBioMedicine 14 (2016) 32–43the combination treatment of SC13 enhances the therapeutic efﬁcacy of
chemotherapy drugs in a xenograft cancer model.
4. Discussion
Chemotherapy remains themost powerful tool for cancer treatment
(Nguyen et al., 2014). Cancer cells are characterized by their ability to
divide rapidly. As a critical enzyme for DNA replication, overexpression
of FEN1 is believed to be a biomarker of cancer cells (Wang et al., 2014;
Abdel-Fatah et al., 2014). Indeed, we and other groups demonstrated
that FEN1 is overexpressed in various types of cancers (Fig. 1). We hy-
pothesized that inhibition of FEN1 could suppress cancer growth by
blocking DNA synthesis. Supporting our hypothesis, siRNA-mediated
downregulation of FEN1 in MCF7 cells retarded cell proliferation signif-
icantly (Fig. 2c). The FEN1 inhibitor SC13 also impaired DNA replication
and cell growth, leading to the accumulation of cells in G1 phase (Fig.
5a–c).
Besides blocking cell division, most anticancer agents used clinically
cause DNA lesions to induce cell apoptosis. However, in many cases, an
elevated DNA repair capacity in cancer cells leads to drug resistance and
severely limits the efﬁcacy of chemotherapeutic drugs (Kaina and
Christmann, 2002). Therapeutic efﬁcacy is determined by the balance
betweenDNAdamage and repair. Given the roles of FEN1 in DNA repair,
we speculated that manipulation of FEN1 in cancer cells could alter the
response of cancer cells to DNA damage agents. Indeed, we demonstrat-
ed that cancer cells with high FEN1 levels are more resistant to DNA
damage agents such as TMZ, cisplatin, and 5FU (Fig. 2i–j). At the same
time, FEN1knockdown sensitizes cancer cells to DNA damage. Further-
more, applying the FEN1 inhibitor SC13 augmented the cytotoxicity of
anticancer drugs, both in cells and in a xenograft cancer mouse model
(Figs. 5-7).
The dual function of FEN1makes it an ideal target for cancer therapy.
The FEN1 inhibitor can be used independently to suppress DNA replica-
tion, inducing DNA damage and apoptosis of cancer cells. Moreover,FEN1 inhibitor can also be combined with other DNA damage-inducing
agents. In addition to suppressing cell growth by inhibitingDNA replica-
tion, FEN1 inhibitor can also lead to the accumulation of DNA DSBs and
genome instability (Fig. 5h, j). Thus, the cytotoxicity induced by FEN1
inhibitor could be due to the combination of defects in DNA replication
and repair.
HR repair is responsible for repairing DNA DSBs in cells (Dudas and
Chovanec, 2004). Therefore, the suppression of FEN1 was expected to
selectively sensitize cancer cells that are defective in HR. Indeed, the
BRAC−/− breast cancer cell line HCC1937 is more sensitive to the
FEN1 inhibitor SC13 when compared to the BRAC+/+ breast cancer
cell line MCF7. The combination of SC13 and PARP1 inhibitors led to ac-
celerated cell apoptosis compared to that observed in cells treated with
SC13 or PARP1 inhibitor alone (Figs. 5i, 6d). These data indicated that
FEN1 is an effective target for developing synthetic lethal interactions
involving the HR pathway.
Besides the genes involved in the HR pathway, N250 genes are pre-
dicted to have a synthetic lethal interaction with FEN1(van Pel et al.,
2013;McManus et al., 2009). FEN1 suppression demonstrated synthetic
lethality with Rad54B in Rad54B-deﬁcient colorectal cancer (CRC) cell
lines, and selectively sensitized hTERT-deﬁcient ALT (Alternative path-
way for lengthening telomeres) cell lines (McManus et al., 2009). Colo-
rectal cancer cells with mutations in CDC4 or MRE11A were extremely
susceptible to knockdown or chemical inhibition of FEN1 (van Pel et
al., 2013). Although this study focused only on breast cancer, we be-
lieved that FEN1 inhibitor could be applied to treat a broad-spectrum
of cancers.
Several attempts to develop FEN1 inhibitors have been described
(Tumey et al., 2004, 2005; McWhirter et al., 2013; Wadhwa and
Jadhav, 2015; Dorjsuren et al., 2011). Tumey et al. reported that N-hy-
droxy urea derivatives are FEN1 inhibitors, and compound #20 has an
impressive IC50 value of 3 nM (Tumey et al., 2005). To our knowledge,
these are the most potent endonuclease inhibitors reported to date.
These compounds sensitize cells to DNA damage-inducing agents,
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42 L. He et al. / EBioMedicine 14 (2016) 32–43such as methyl methane sulfonate treatment. However, when used
alone, its inhibitory effects on cell proliferation is low. Based on the
structure of compound #20, we used pyrrolo[3.2-d]pyrimidine as a
new pharmacophore and replaced the hydrophilic hydroxyl groups of
urea with n-propyl building blocks. The resulting compound is more
permeable to cells and introduces more cytotoxicity. For example,
SC13 inhibits cell growth by N20% at 5 μM,while theN-hydroxy urea de-
rivatives inhibit cell growth by b3% at the same concentration (Fig. 6a
and data not shown).
We demonstrated that FEN1 is overexpressed in breast cancer cells
and is essential for cancer cell proliferation. FEN1 enhances the resis-
tance of cancer cells to chemotherapeutic agents that induce DNA le-
sions. Knockdown of FEN1 expression or SC13-mediated inhibition of
FEN1 activity suppresses cell growth and sensitizes cancer cells to
DNA damage-inducing drugs, both in cells and in an animal model. Fur-
ther studies are underway to evaluate the clinical usefulness of this
compound as a cancer therapy.
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